Condition: Oligometastatic Non-small Cell Lung Cancer (NSCLC) · Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study
This description comes directly from the study's public registry record.
Antonin LÉVY, MD · +33 (0)1 42 11 47 57 · antonin.levy@gustaveroussy.fr
Always discuss trial participation with your own doctor first.
| Institut de Radiothérapie du Sud de l'Oise | Creil, Hauts-de-France, France | Recruiting |
| Centre Sainte-Catherine | Avignon, Provence-Alpes-Côte d'Azur Region, France | Recruiting |
| Gustave Roussy | Villejuif, Île-de-France Region, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06840782